StreetInsider.com News Articles

Form 10-K AYTU BIOPHARMA, INC For: Jun 30

Tue, 22 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260922/27091240.html

Aytu BioScience (AYTU) Tops Q4 EPS by 28c

Tue, 22 Sep 2026 16:14:10 -0400

Aytu BioScience (NASDAQ: AYTU) reported Q4 EPS of $0.00, $0.28 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $12.28 million.

For earnings history and earnings-related data on Aytu BioScience (AYTU) click here.

Form 8-K AYTU BIOPHARMA, INC For: Sep 22

Tue, 22 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260922/27091077.html

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Tue, 22 Sep 2026 16:05:00 -0400

DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 full year and fourth quarter.

Q4 Fiscal 2026 Highlights

Net revenue increased 6.4% to $16.1 million versus $15.1 million in Q4 fiscal 2025.
EXXUA net revenue was $3.9 million during Q4 fiscal 2026, the first full quarter of launch.
ADHD Portfolio net revenue was $10.4 million

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Tue, 22 Sep 2026 16:05:00 -0400

Q4 Fiscal 2026 Highlights

Net revenue increased 6.4% to $16.1 million versus $15.1 million in Q4 fiscal 2025.
EXXUA net revenue was $3.9 million during Q4 fiscal 2026, the first full quarter of launch.
ADHD Portfolio net revenue was $10.4 million

Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026

Wed, 16 Sep 2026 16:30:00 -0400

DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m. Eastern time, to review the results followed by

Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026

Wed, 16 Sep 2026 16:30:00 -0400

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: LYTTON LAURENCE W

Fri, 14 Aug 2026 12:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26927625.html

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: LYTTON LAURENCE W

Fri, 14 Aug 2026 12:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26927625.html

Form 4 AYTU BIOPHARMA, INC For: Jul 28 Filed by: Disbrow Jarrett